Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × rrCLL × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 368 Lymphoma, Non-Hodgkin 344 Leukemia, Lymphocytic, Chronic, B-Cell 320 Precursor Cell Lymphoblastic Leukemia-Lymphoma 289 Lymphoma, Large B-Cell, Diffuse 240 Lymphoma, Follicular 233 Leukemia 196 Hodgkin Disease 168 Lymphoma, Mantle-Cell 163 Leukemia, Myeloid, Acute 159 Multiple Myeloma 133 Myelodysplastic Syndromes 130 Recurrence 123 Burkitt Lymphoma 121 Lymphoma, B-Cell, Marginal Zone 119 Lymphoma, T-Cell, Cutaneous 92 Mycosis Fungoides 82 Lymphoma, B-Cell 81 Neoplasms 79 Waldenstrom Macroglobulinemia 74 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 69 Sezary Syndrome 67 Lymphoma, Large-Cell, Immunoblastic 65 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 56 Lymphoma, Large-Cell, Anaplastic 53 Neoplasms, Plasma Cell 52 Myeloproliferative Disorders 52 Primary Myelofibrosis 45 Hematologic Neoplasms 43 Blast Crisis 43

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡